Glenmark’s innovative immune-oncology drug for advanced solid tumors and lymphomas receives FDA acceptance for Phase 1/2 clinical study

Glenmark Pharmaceuticals Ltd.’s subsidiary, Glenmark Specialty SA, has achieved a breakthrough in the fight against advanced solid tumors and lymphomas. The US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for GRC 54276, an…